This is some text inside of a div block.

Cost-effective GLP-1 coverage for employers: the complete guide

Nicholas Syhler

November 6, 2026

min read

Last updated October 2026 · 9 min read

TL;DR

Among employers that cover GLP-1s for weight loss, the drugs averaged 11.4% of total annual claims in 2025, and more than 15% for 26% of them [1].
Coverage is pulling back: the share of large employers covering GLP-1s for weight management fell from 72% in 2025 to 60% in 2026 [2].
Your GLP-1 cost comes down to four variables you can design for: who is eligible, how long members stay on medication, how much medication is dispensed and the net price you pay.
A behavior-first program with a planned taper works on duration and dose. In Embla's TRIM study, members lost 16.7% of body weight on average over 64 weeks using 55% less GLP-1 medication [3].

Why is GLP-1 coverage so hard to make cost-effective?

GLP-1 coverage is hard to make cost-effective because the drugs are expensive, demand is broad and most of the benefit fades when treatment stops. About 12% of US adults say they currently take a GLP-1 drug, for weight loss or another condition [4]. Among firms with 1,000 to 4,999 workers that cover GLP-1s for weight loss, 44% say utilization was higher than expected [5].

The bigger issue is what the spend buys. One year after stopping semaglutide 2.4 mg and the trial's lifestyle program, STEP 1 participants had regained 11.6 percentage points of the 17.3% they had lost [6]. Paying for a course of treatment that ends without lasting behavior change buys little. We cover the regain problem in weight regain after stopping GLP-1s, and the price side in how much GLP-1s cost self-funded employers.

What are your GLP-1 coverage options?

Self-funded employers have five realistic options, ranging from no coverage to a fully managed program outside the medical plan.

Exclude GLP-1s for weight loss. This removes the claims line but not the demand. Wegovy is sold direct to consumers at $349 a month for most doses [7], and 27% of insured GLP-1 users say they paid the full cost themselves [4]. We look at this trade-off in the GLP-1 dilemma.
Cover through your PBM with utilization management. This is the default: 79% of covering employers use utilization management, and 95% of those require prior authorization [1]. It controls who starts but rarely what happens afterwards. See GLP-1 coverage without the PBM.
Cover with conditions. 34% of firms covering GLP-1s for weight loss now require members to see a dietitian, case manager or therapist, or join a lifestyle program, up from 10% in 2024 [5]. For the semaglutide decision specifically, read should employers cover Wegovy.
Use a manufacturer pathway. Eli Lilly offers employers a direct pathway to Zepbound at a list price of $449 a month [8], and Novo Nordisk will cut the US list price of Wegovy, Ozempic and Rybelsus to $675 a month from January 1, 2027 [9].
Carve out a managed program. A separate vendor runs eligibility, coaching, prescribing through licensed clinicians and reporting outside your medical plan. See what a carve-out benefit is.

Most employers combine several of these. For a lever-by-lever comparison of what each saves, read how to offer GLP-1s without blowing the budget.

Who should be eligible for GLP-1 coverage?

Eligibility should combine clinical criteria with a commitment to behavior change, not BMI alone. Among employers that set eligibility requirements, 90% use a minimum BMI, 54% require obesity plus another chronic condition and 29% require a lifestyle modification program [1].

Three design choices make eligibility do more work:

Tie access to engagement. Members who join coaching before or alongside medication give you a reason to expect lasting change.
Re-authorize on progress, not on time. Renewal should depend on clinical progress and engagement, not on a refill date.
Offer a non-medication track. Employees who do not qualify, or prefer not to take medication, still need support. A coaching-only program such as EmblaThrive covers that group.

Case study: over 70% lower GLP-1 costs in ten months. One self-funded employer kept GLP-1 access open, cut GLP-1 costs by over 70% and broke even in year one. Download the case study

How do dose and duration drive GLP-1 cost?

Spend is roughly the number of members on medication, times the months they stay on it, times the net cost per month, so duration is the biggest lever after eligibility. Only 8% of commercially insured adults without diabetes who started a GLP-1 for obesity were still on it three years later [10]. In one health system, 47.6% of people who stopped within a year did so because of cost or insurance issues, and 14.6% because of side effects [11].

That means a large share of spend goes on courses that stop early. Adults who stopped within three months had lost 3.6% of body weight at one year, compared with 11.9% for those who stayed on treatment [12]. Standard protocols titrate toward the maximum approved dose, such as 2.4 mg a week for semaglutide. How dose turns into cost depends on the product and your pricing arrangement, because list prices are often the same across doses [9]. Ask your PBM or vendor to show it with your own data. Our GLP-1 spend diagnostic walks through each driver.

Why does coverage need a tapering plan?

Without a planned exit, GLP-1 coverage becomes indefinite by default, and abrupt stops tend to undo the result. In STEP 4, participants switched from semaglutide to placebo regained 6.9% of body weight over 48 weeks, while those who continued lost a further 7.9% [13]. In SURMOUNT-4, participants switched from tirzepatide to placebo regained 14.0% over 52 weeks [14].

Those trials tested a sudden switch to placebo, not a gradual, supported taper. The lesson for plan design is that the exit needs to be planned from the start: clear criteria for when to step down, a gradual reduction and continued behavioral support. Read more in our guide to GLP-1 tapering for employers.

What should you measure?

Measure outcomes and medication use, not enrollment. Agree on the reporting set with your vendor or PBM before launch.

Clinical: average percentage weight change at fixed intervals, and the share of members reaching 5% and 10% loss.
Medication: members on medication, average dose, months on medication, and the share stepping down or stopping.
Engagement: coaching sessions attended and retention in the program.
Financial: net GLP-1 spend per engaged member, and obesity-related claims over two to three years.

For time horizons and what to ask vendors for, see the true ROI of covering weight loss medication.

How does Embla approach cost-effective coverage?

Embla is a behavior-first program that runs outside the medical plan as a carve-out. Members get 1:1 coaching based on Acceptance and Commitment Therapy. When medication is appropriate, independent licensed clinicians prescribe it under a treat-to-target protocol that aims for the lowest effective dose, and a structured taper begins at month 16 over 12 weeks.

In the TRIM study of 2,694 adults in Denmark, members lost 16.7% of body weight on average over 64 weeks on an average semaglutide dose of about 1.08 mg a week, less than half the standard maximum dose. They used 55% less GLP-1 medication [3]. In Embla's program, 78.5% of members tapered or stopped GLP-1s. In one self-funded employer over ten months, GLP-1 costs fell by over 70% (read the case study). See how medication fits the program on EmblaThriveMD.

Checklist: designing cost-effective GLP-1 coverage

Pull two years of GLP-1 claims: new starts, months on therapy, net cost per fill and the share who stopped.
Pick your coverage option and model each scenario with the Embla savings calculator.
Write eligibility rules that include engagement in a behavior program, not BMI alone.
Require a written dose policy and tapering plan from your PBM or vendor.
Agree on outcome and medication reporting before launch, and set a review point after the first plan year.

Frequently asked questions

Is it cheaper to stop covering GLP-1s?

It removes the pharmacy line, but not the underlying cost. Obesity accounts for nearly $173 billion a year in US medical spending, about $1,861 more per person than for adults at a healthy weight (2019 dollars) [15]. Many employees will also keep using GLP-1s at their own expense.

Do lower GLP-1 doses still produce meaningful weight loss?

In Embla's real-world TRIM study, members reached 16.7% average weight loss over 64 weeks on an average dose of about 1.08 mg a week, and weight change was consistent across dose levels [3]. Lower doses work best alongside structured behavioral support.

How many employees will use GLP-1 coverage?

It varies, and many employers underestimate it: 44% of firms with 1,000 to 4,999 workers that cover GLP-1s for weight loss say utilization beat expectations [5]. Model a range of 3% to 8% of your population and check it against your claims after six months.

Can we cover GLP-1s outside our PBM?

Yes. A carve-out program sits outside the medical and pharmacy plan, so it does not require plan integration. See GLP-1 coverage without the PBM for how that works.

References

International Foundation of Employee Benefit Plans, reported by Becker's Hospital Review. Employer coverage of GLP-1s for diabetes, weight loss remains steady at 36%: survey. Becker's Hospital Review, 2026. Link
Business Group on Health, reported by Insurance Business. More employers are dropping GLP-1 weight loss coverage before open enrollment. Insurance Business, 2026. Link
Seier S, Stamp-Larsen K, Jensen SBK, Torekov SS, Gudbergsen H. Treat to target in weight management with semaglutide: real-world evidence from an eHealth clinic (TRIM study). Diabetes, Obesity and Metabolism, 2025. Link
KFF. Poll: 1 in 8 adults say they are currently taking a GLP-1 drug for weight loss, diabetes or another condition, even as half say the drugs are difficult to afford. KFF Health Tracking Poll, 2025. Link
Cotter L, Rae M, McGough M, et al.. Perspectives from employers on the costs and issues associated with covering GLP-1 agonists for weight loss. Peterson-KFF Health System Tracker, 2025. Link
Wilding JPH, Batterham RL, Davies M, et al.. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes, Obesity and Metabolism, 2022. Link
Novo Nordisk. Wegovy price guide. NovoCare, 2026. Link
Becker's Hospital Review. Employers' GLP-1 coverage dilemma grows. Becker's Hospital Review, 2026. Link
Novo Nordisk. Novo Nordisk announces significant reduction in US list price for Wegovy, Ozempic and Rybelsus. Novo Nordisk press release, 2026. Link
Prime Therapeutics. Prime Therapeutics' leading research shows only 1 in 12 remain on a GLP-1 drug for obesity at three years. Press release via BioSpace, 2025. Link
Gasoyan H, Butsch WS, Casacchia NJ, et al.. Reasons for discontinuation of obesity pharmacotherapy with semaglutide or tirzepatide in clinical practice. Obesity, 2025. Link
Gasoyan H, Butsch WS, Schulte R, et al.. Changes in weight and glycemic control following obesity treatment with semaglutide or tirzepatide by discontinuation status. Obesity, 2025. Link
Rubino D, Abrahamsson N, Davies M, et al.. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA, 2021. Link
Aronne LJ, Sattar N, Horn DB, et al.. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA, 2024. Link
Centers for Disease Control and Prevention. Adult obesity facts. CDC, accessed 2026. Link